
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings is a digital healthcare company with a strong focus on creating trusted solutions for the detection, prediction, and prevention of disease. Their flagship product, the Zio System, combines a wire-free, patch-based 14-day wearable biosensor with a cloud-based data analytic software, providing clinicians with an efficient and accurate means of diagnosing arrhythmias. With a durable revenue growth profile and steady progress in profitability, there is potential for iRhythm to generate double-digit revenue growth and see further improvement in their margin and operating losses. Potential upside drivers include higher ambulatory cardiac testing volume growth, higher revenue growth, and faster international expansion, while risks include sales execution, increased competition, and negative reimbursement developments. With an estimated 17-18% revenue growth for 2026 and potential growth catalysts in the form of further expansion into new channels and categories, the future looks promising for iRhythm.
Bears say
iRhythm Holdings is facing several potential risks that can negatively impact its financials, including reduced commercial reimbursement rates, increased competition, and negative developments in sales execution and reimbursement. However, the company remains confident in its future growth potential, driven by strong demand for its Zio System and the expansion of its channel partner network. Investors should closely monitor these risks while also considering the potential for upside due to higher testing volume and revenue growth, as well as the company's goal to achieve $1 billion in revenue and 15% EBITDA margin by 2027.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares